Related Experiment Video
Updated: Dec 31, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Polymeric Nanoparticles for the Treatment of Malignant Gliomas
Basant Salah Mahmoud1,2, Ali Hamod AlAmri1,3, Christopher McConville1
1College of Medical and Dental Sciences, School of Pharmacy, University of Birmingham, Birmingham B15 2TT, UK.
Abstract:
Malignant gliomas are one of the deadliest forms of brain cancer and despite advancements in treatment, patient prognosis remains poor, with an average survival of 15 months. Treatment using conventional chemotherapy does not deliver the required drug dose to the tumour site, owing to insufficient blood brain barrier (BBB) penetration, especially by hydrophilic drugs. Additionally, low molecular weight drugs cannot achieve specific accumulation in cancerous tissues and are characterized by a short circulation half-life. Nanoparticles can be designed to cross the BBB and deliver their drugs within the brain, thus improving their effectiveness for treatment when compared to administration of the free drug. The efficacy of nanoparticles can be enhanced by surface PEGylation to allow more specificity towards tumour receptors. This review will provide an overview of the different therapeutic strategies for the treatment of malignant gliomas, risk factors entailing them as well as the latest developments for brain drug delivery. It will also address the potential of polymeric nanoparticles in the treatment of malignant gliomas, including the importance of their coating and functionalization on their ability to cross the BBB and the chemistry underlying that.
Insights
Malignant gliomas are deadly brain cancers with poor prognoses. Nanoparticles offer improved drug delivery across the blood-brain barrier (BBB), enhancing malignant glioma treatment efficacy.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Drug Delivery Systems
Background:
- Malignant gliomas are aggressive brain tumors with limited treatment options and poor patient survival rates.
- Conventional chemotherapy faces challenges in penetrating the blood-brain barrier (BBB), hindering effective drug delivery to the tumor site.
- Low molecular weight drugs exhibit poor tumor specificity and short circulation half-lives, further complicating treatment.
Purpose of the Study:
- To review therapeutic strategies for malignant gliomas, focusing on overcoming BBB limitations.
- To explore the potential of polymeric nanoparticles for targeted brain drug delivery in glioma treatment.
- To discuss the role of nanoparticle surface modification, such as PEGylation, in enhancing BBB penetration and tumor specificity.
Main Methods:
- Literature review of current therapeutic strategies for malignant gliomas.
- Analysis of nanoparticle-based drug delivery systems for brain cancer.
- Examination of the chemical principles behind nanoparticle design for BBB crossing and tumor targeting.
Main Results:
- Nanoparticles demonstrate potential to overcome BBB penetration issues, enabling higher drug concentrations at the tumor site.
- Surface modifications like PEGylation can improve nanoparticle targeting to glioma receptors and enhance efficacy.
- Polymeric nanoparticles offer a versatile platform for developing advanced brain drug delivery systems.
Conclusions:
- Nanoparticle-based strategies, particularly polymeric nanoparticles with functionalized surfaces, show significant promise for improving malignant glioma treatment.
- Optimizing nanoparticle design for BBB crossing and tumor-specific delivery is crucial for enhancing therapeutic outcomes.
- Further research into nanoparticle chemistry and functionalization is essential for advancing brain cancer drug delivery.
